

Decompensated Liver Disease on the waiting list :

Treatment Experienced Genotype 3



Professor Geoff McCaughan
AW Morrow Gastroenterology and Liver Centre
Australian National Liver Transplant Unit
Royal Prince Alfred Hospital, Sydney



'Peter'

Case 1

44 year old man

- **HCV Genotype 3**; Viral load 4.93 log₁₀ IU/mL
- **MELD 20**
- CPS 11-LTX waiting list
 - Ascites – weekly LVP:
 - SBP
- Treat with SOF plus DCV for 24 weeks (compassionate access programme)
- Albumin improves (infusions)
- **MELD down to 17 week 16**

'Peter'

Case 1

- Despite biochemical improvement, episodic HE, N and V, pleural effusions, weekly LVP. Remained prioritised for liver transplantation
- Successful LTx at week 16 on treatment
- Treatment continued to week 24
- SVR post LTx
- Doing well 12 mnths post LTx

'Gary'

Case 2

51 year old man

- **HCV Genotype 3; Viral Load Log 6**
- **MELD 18;**
- **CPS 10 –LTX waiting list**
 - Ascites – weekly LVP:
 - large umbilical hernia
- **Treat with SOF plus DCV for 24 weeks (compassionate access programme)**
- **MELD down to 14 at week 24**



'Gary'

Case 2

- SVR
- But still requiring taps (second weekly)
- Main issue is the huge umbilical hernia
- Surgeons will not operate without ascites being controlled
- Considering TIPPS -not done
- 8 mnths post SVR
 - **MELD 12**
 - No ascites
 - Can get huge umbilical hernia fixed
 - Removed from LTx waiting list
- 2 weeks ago –succesfull hernia repair !!!

'Chris'

Case 3

46 yrs year old man



- HCV **Genotype 3**; viral load Log 6
- **MELD 18**;
- CPS 10
 - Ascites – weekly LVP:
 - SBP
 - Intermittent episodes of HE (violent toward partner)
- Treat with SOF plus DCV for 24 weeks (compassionate access programme)
- **MELD down to 15 at week 24**
 - still requiring taps

'Chris'

Case 3

- Virological relapse at 3 months post EOT
- Ascites less
- MELD stable
- Routine 6 month surveillance CT
 - 23cm central HCC → TACE
- Progressive HCC (vascular invasion) despite TACE
 - Outside of LTx criteria
 - Progressive jaundice , ascites , HRS
 - Died 8 months post relapse

The Toscar Study: 24 weeks of SOF + DAC in decompensated HCV with MELD \geq 15




N = 111

51 (46%)
G3

Results - Baseline data:


n = 117

Median = C10



CPT score

Mean = 17




MELD score

77% ascites

61% encephalopathy

Results: Early biochemical response:



Results - Treatment response

- N=111
 - Genotype 3 = 51
 - 46 week 36 f/u
 - 4/ 46 breakthrough (EOT PCR +)
 - 8 / 46 relapse

12 / 46 treatment failure (26%)

SVR 74%

18/22 (81%) Previous PR

16/24(66%) no PR


3 DEATHS (1,2 5 mnth)

11 TRANSPLANTED

- 5 POST TREATMENT (2 PCR+)

- 6 ON TREATMENT (All PCR neg)

**DECOMPENSATED CIRRHOSIS ; TREATMENT EXPERIENCED G3
ON THE WAITING LIST :
TREATMENT : SOF + DAC +RIBA for 24 weeks**



Questions: G3 Decompensated

- Ribavarin for all –YES
- 24 weeks?
- Will SOF + Velpatasvir results be better – yes?
(15-20% NS5A resistance) – what then ?
- Will Velpatasvir treat Dac induced NS5A resistance ? (need SOF+ Dac +PI but PI contraindicated in Decompensated Disease)